158 articles on protocols, safety, clinical data, and peptide science.
ARA-290 (cibinetide) is an EPO-derived peptide studied for small-fibre neuropathy. Here is the evidence-first read on what the human trials show and what they don't.
A practical guide to reading peptide research in 2026: trial design, evidence levels, safety signals, regulatory context, and what to track.
A new Scientific Reports rat study tested BPC-157 in skeletal muscle ischemia-reperfusion injury. Here is what it found and what it does not prove.
New 2025 and 2026 eye-health studies link GLP-1 receptor agonists with age-related macular degeneration outcomes. Here is the evidence-first read.
A 2026 study links lower MOTS-c and humanin signals with atrial fibrillation tissue, fibrosis, mitochondrial dysfunction, and AF inducibility in models.
A 2026 pilot study links MOTS-c with oxidative stress and arterial stiffness in peritoneal dialysis patients. Here is what it means and what it does not prove.
A 2026 meta-analysis found preoperative GLP-1 use may support modest weight loss before bariatric surgery, but tracking and surgical-team planning matter.
A recruiting Phase 2 trial is testing topical GHK-Cu gel for acute skin wound healing. Learn what the study measures, why route matters, and what remains unproven.
MOTS-c is moving from mitochondrial metabolism theory into a Phase 2a prediabetes trial. Learn what the trial measures, what animal data suggests, and what still is not proven.
Lilly's TRIUMPH-1 retatrutide Phase 3 readout showed 28.3% weight loss at 80 weeks. Learn what the dose data means and how to track response safely.
FDA's July 2026 PCAC meeting will review seven peptide-related bulk drug substances. Learn what it can change, what it cannot, and how to track protocol decisions clearly.
The 2026 peptide market is shifting from hype to oversight. Learn how to evaluate sourcing, compounding status, research labels, and safety signals.
